Novo Nordisk A/S (NYSE:NVO) has disclosed that it retains approximately 60% of the list price of its diabetes and obesity medications, Ozempic and Wegovy, in the U.S. after accounting for rebates and fees paid to intermediaries. This revelation comes amid intensifying scrutiny over the cost of these blockbuster drugs. In a recent letter to Senator Bernie Sanders, the European drug maker expressed willingness to collaborate with lawmakers to tackle systemic issues hindering patients’ access to medications. The letter highlighted the company’s stance that focusing solely on the list price is misleading, given the significant portion paid to middlemen in the complex U.S. healthcare system. Senator Sanders has been urging Novo to reduce the prices of Wegovy, emphasizing the disparity between ...